RGMP — Regnum Share Price
0.000.00%
Last trade - 00:00- $0.00m
- $1.11m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | 0.01 | 0.01 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +40 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Regnum Corp. is focused on developing and commercializing therapeutics that treat rare and infectious diseases, specifically in populations that are neglected or face adherence challenges due to inconvenient dosing or delivery system, tolerability, or cost and accessibility of available therapeutic options. The Company's primary asset is the commercial rights to leronlimab (PRO 140) in all human immunodeficiency virus (HIV) indications within the United States. Leronlimab is a monoclonal antibody. The target of leronlimab is the immunologic receptor CCR5. Leronlimab prevents certain strains of HIV from using the CCR5 receptor as an entry gateway for healthy cells. The leronlimab antibody belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. Leronlimab blocks HIV from entering a cell by binding to a molecule called CCR5 referred to as R5 strains, attach as part of HIVs entry into a cell.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- March 31st, 2016
- Public Since
- March 15th, 2019
- No. of Shareholders
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 22,950,000
- Address
- 600 THIRD AVENUE, 10TH, NEW YORK, 10016
- Web
- http://www.regnumcorp.com/
- Phone
- +1 9176471498
- Auditors
- GreenGrowth CPAs
Upcoming Events for RGMP
Similar to RGMP
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Regnum share price?
As of Today at 19:18 UTC, shares in Regnum are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Regnum share price performed this year?
Shares in Regnum last closed at $0.00 and the price had moved by -99.96% over the past 365 days. In terms of relative price strength the Regnum share price has underperformed the S&P500 Index by -99.96% over the past year.
What are the analyst and broker recommendations for Regnum?
There is no consensus recommendation for this security.
What is the Regnum dividend yield?
Regnum does not currently pay a dividend.
Does Regnum pay a dividend?
Regnum does not currently pay a dividend.
When does Regnum next pay dividends?
Regnum does not currently pay a dividend.
How do I buy Regnum shares?
To buy shares in Regnum you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Regnum?
As of the previous close price of $0.00, shares in Regnum had a market capitalisation of $0.00m.
Where are Regnum shares listed?
Here are the trading details for Regnum:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RGMP
What kind of share is Regnum?
Based on an overall assessment of its quality, value and momentum Regnum is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Regnum share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Regnum share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Regnum. Over the past six months, its share price has underperformed the S&P500 Index by -99.86%.
As of the last closing price of $0.00, shares in Regnum were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Regnum PE Ratio?
The Regnum PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Regnum?
We do not have data on Regnum's directors